Comparing Day 6 and Day 7 Blastocyst Transfers in Frozen HRT Cycles
Optimal Timing of Euploid Day 6 Blastocyst (blastocyst Which Was Biopsied on Day 6 After Fertilization) Transfer in Frozen Hormonal Replacement Therapy Cycles: Day 6 or Day 7 of Progesterone Administration?
PHASE1 · ART Fertility Clinics LLC · NCT05980091
This study is testing whether transferring frozen embryos on day 6 or day 7 of hormone treatment can lead to better pregnancy outcomes for women using frozen embryo transfers.
Quick facts
| Phase | PHASE1 |
|---|---|
| Study type | Interventional |
| Enrollment | 316 (estimated) |
| Ages | 18 Years to 43 Years |
| Sex | Female |
| Sponsor | ART Fertility Clinics LLC (other) |
| Locations | 2 sites (Abu Dhabi, Abu Dhabi Emirate and 1 other locations) |
| Trial ID | NCT05980091 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the clinical pregnancy, miscarriage, and live birth rates associated with transferring euploid day 6 blastocysts on either the 6th or 7th day of progesterone administration in Hormonal Replacement Therapy (HRT) frozen embryo transfer cycles. It is a prospective and randomized trial that will focus exclusively on euploid embryos to eliminate aneuploidy as a factor in implantation failure. The research seeks to determine the optimal timing for embryo transfer to enhance pregnancy outcomes by ensuring synchronization between the embryo and the endometrial window of implantation.
Who should consider this trial
Good fit: Ideal candidates include women aged 18 to 43 with at least one euploid cryopreserved day 6 blastocyst of Grade BB quality.
Not a fit: Patients with uterine abnormalities, hydrosalpinx, or any contraindications to estradiol or progesterone may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve pregnancy rates for women undergoing frozen embryo transfers.
How similar studies have performed: This approach is novel, as it is the first prospective study specifically examining euploid day 6 blastocyst transfers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women aged 18 years to 43 years. * Having at least 1 euploid cryopreserved day 6 blastocyst of at least Grade BB quality. * Endometrial trilaminar appearance on the day of progesterone start Exclusion Criteria: * Uterine abnormality * Hydrosalpinx * Asherman syndrome * Any known contraindications or allergy to oral estradiol or progesterone. * Intention to treat : exclusion factors : 1. Spontaneous ovulation HRT cycle 2. Discontinuation of HRT medication
Where this trial is running
Abu Dhabi, Abu Dhabi Emirate and 1 other locations
- ART Fertility Clinics LLC — Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates (RECRUITING)
- ART Fertility Clinics Dubai — Dubai, United Arab Emirates (RECRUITING)
Study contacts
- Principal investigator: Carol Coughlan, PhD — ART Fertility Clinics LLC
- Study coordinator: Barbara Lawrenz, PhD
- Email: barbara.lawrenz@artfertilityclinics.com
- Phone: +971 800 337845489
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Infertility, Fertility Issues, Infertility, Female, Implantation, Blastocyst, HRT, Progesterone